Title: Graves' Hyperthyroidism after Stopping Immune Suppressive Therapy in Type 1 Diabetic Islet Cell Recipients with Pretransplant TPO-Autoantibodies
Authors: Gillard, Pieter ×
Huurman, Volkert
Van der Auwera, Bart
Decallonne, Brigitte
Poppe, Kris
Roep, Bart O
Gorus, Frans
Mathieu, Chantal
Pipeleers, Daniel
Keymeulen, Bart #
Issue Date: Oct-2009
Publisher: American Diabetes Association
Series Title: Diabetes care vol:32 issue:10 pages:1817-9
Abstract: Objective: After an initially successful islet cell transplantation, a number of patients return to C-peptide-negativity and are therefore discontinued in immune suppressive therapy. Some were found to develop Graves' disease. Research design and methods: Immune suppressive therapy was stopped in 13 type 1 diabetic islet cell recipients who had received one course of antithymocyte globulin and maintenance doses of mycophenolate mofetil and a calcineurin inhibitor. None had a history of thyroid disease. Results: In 4 patients clinical Graves' hyperthyroidism was observed within 21 months after discontinuation, and 30 to 71 months after start of immune suppressive therapy. All four exhibited a pretransplant positivity for thyroid peroxidase (TPO)-autoantibodies while the nine others were TPO-negative pre- and posttransplantation. Conclusions: Type 1 diabetic recipients of islet cell grafts with pretransplant TPO-autoantibody positivity exhibit a high risk for developing Graves' hyperthyroidism after immune suppressive therapy is discontinued for a failing graft.
ISSN: 0149-5992
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science